Background: The effects of HIV infection and antiretroviral therapy (ART) on usual lipid levels have been reported. The effects of initiating versus deferring ART on high-density and low-density lipoprotein particle (HDL-P and LDL-P, respectively) concentrations and apolipoprotein (Apo) levels are not well described.
Introduction
Pro-atherogenic changes in blood lipids and lipoproteins, both as a consequence of HIV infection and exposure to antiretroviral therapy (ART), are associated with an increased risk of cardiovascular disease (CVD) among HIV-infected individuals [1] . Serum lipid levels uniformly decline following HIV sero-conversion [2] . Among untreated HIV-infected participants, highdensity lipoprotein cholesterol (HDL-C) levels are inversely correlated with HIV RNA levels [3] . HIV treatment with ART leads to a rise in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) that typically exceeds preinfection levels, whereas the recovery of HDL-C following ART initiation may be incomplete [2] . The effect of HIV infection on HDL-C is, in part, a consequence of a nonspecific inflammatory response as well as a direct effect of HIV itself on HDL metabolism and reverse cholesterol transport [4] [5] [6] .
Methods utilizing NMR spectroscopy are able to 'count' numbers of lipoprotein particles based on their size, which provides an assessment of lipoprotein particle structure beyond traditional lipid fraction measures of the cholesterol content within those particles (e.g., HDL-C) [7, 8] . Estimates of lipoprotein particle size and concentration, as well as measures of lipid-associated apolipoproteins (Apo), may have advantages over traditional cholesterol measures in terms of predicting CVD risk [8] [9] [10] [11] [12] [13] . ApoB and ApoA1 are the signature proteins of LDL and HDL particles (LDL-P and HDL-P), respectively, and the ratio of ApoB to ApoA1 is one means of assessing the balance of cholesterol transport and atherogenic potential [12] . Importantly, LDL-P, HDL-P, ApoB, and ApoA1 can been reliably measured with nonfasting specimens [7] .
In the Strategies for Management of AntiRetroviral Therapy (SMART) trial, some participants were not taking ART at entry. For these participants, the study design allowed a randomized comparison between immediately initiating versus deferring ART. We compare these two treatment groups for changes in lipoprotein particle concentrations and Apo, and determine baseline predictors of changes in these measures following the initiation of ART. Our general aim was to further characterize HIVassociated dyslipidemia and assess how ART modified it.
Methods
The methods and results of the SMART trial, including the subgroup not taking ARTat entry, have been reported [14] [15] [16] .
Study population
Of the 5472 randomized participants in the SMART trial, 477 had never taken ARTor had not used ART for at least 6 months prior to randomization (henceforth referred to as the 'no-ART' subgroup). To reduce the likelihood of recent ART exposure, participants with low HIV RNA levels (<10 000 copies/ml) during the 6 months before randomization were not included in this no-ART subgroup. Among the 477 participants in this no-ART subgroup, 254 consented to have plasma specimens stored every 2 months during the first year following randomization and form the basis of this report. For these participants, the randomized intervention in SMART of drug conservation or viral suppression strategy was a comparison of immediate versus deferred (until CD4 cell counts declined to 250 cells/ml) initiation of ART, respectively [15] .
The SMART study protocol was approved by the institutional review board (IRB) or ethics committee at each clinical site and at the University of Minnesota, which served as the Statistical and Data Management Center. The IRB at the University of Minnesota also approved plans for analysis of stored specimens for consenting participants.
Lipids, lipoprotein particles, apolipoproteins, and inflammatory biomarkers
Traditional serum lipids were measured at baseline by Quest Diagnostics Inc. (Madison, New Jersey, USA) using standard enzymatic methods. LDL-C was directly measured. CD4 cell count and HIV RNA levels were measured at clinical sites. For consenting participants in the SMART trial, plasma specimens were collected using EDTA tubes, processed within 4 h of collection, frozen at À708C and shipped to a central repository where they continued to be stored at À708C. Samples were not required to be fasting specimens.
Lipoprotein particle size and concentration was estimated by an automated proton NMR spectroscopic assay at LipoScience Inc. (Raleigh, North Carolina, USA), as previously described [7] . Lipoprotein class was categorized by particle diameter as very low density lipoprotein (VLDL) (27-200 nm) , LDL (18-27 nm), and HDL (7.3-13 nm). Lipoprotein particle subclasses were further categorized by HDL-P diameter as large (8.8-13 .0 nm), medium (8.2-8.8 nm), and small (7.3-8.2 nm) and by LDL particle diameter as large (21.3-23 nm) and small (18.3-21.2 nm). Lipoprotein particle concentrations (mmol/l for HDL and nmol/l for other measures) were then determined from the measured amplitudes of NMR signals, and are denoted by 'P' (e.g., HDL-P).
Levels of the HDL-associated ApoA1 and the LDLassociated ApoB were measured by the Laboratory for Clinical Biochemistry Research at the University of Vermont. ApoA1 antigen and ApoB antigen were measured using the BNIInephelometer (N Antiserum to Human ApoAI and ApoB, respectively; Dade Behring Inc., Deerfield, Illinois, USA). The amount of ApoA1 and ApoB present in the sample is quantitatively determined by assessing the intensity of light scattered by antigen-antibody molecules. Expected values for ApoA1 in normal, healthy individuals range from 1.25 to 2.15 g/l in women and 1.10 to 2.05 g/l in men. Expected values for ApoB in normal, healthy individuals range from 55 to 125 mg/dl in women and 55 to 140 mg/dl in men. The average interassay coefficient of variation for this project was 4.2% for ApoA1 and 3.6% for ApoB. Two inflammatory biomarkers [high-sensitivity C-reactive protein (hsCRP) and interleukin 6 (IL-6)] were also measured at the University of Vermont using methods previously reported [17] . All samples were analyzed blinded to treatment group.
Statistical methods
Unless otherwise stated, comparisons between the viral suppression and drug conservation groups are intent-totreat (all randomized participants in the no-ART subgroup consenting to the storage of specimens are included in the analysis). An analysis is also carried out in which one viral suppression participant who did not initiate ART and 14 drug conservation participants who initiated ART before 6 months are excluded. Simple descriptive statistics are used for baseline cross-sectional analyses. Analysis of covariance with the baseline level of the biomarker included as a covariate was used to compare treatments for changes in total VLDL particle (VLDL-P), total LDL-P, total HDL-P, and HDL-P subclass concentrations and ApoA1 and ApoB levels at 2 and 6 months. Analysis of covariance models that included interaction terms between treatment group and baseline variables were used for subgroup analyses. Multiple regression analysis is used to study predictors of change after 6 months for viral suppression participants. The following predictors were age, sex, race, hepatitis (B or C) co-infection, smoking, blood pressure lowering medication, lipid-lowering medication, BMI, diabetes, CD4 þ cell count, HIV RNA level (log 10 transformed), naive to all ART (or not), prior AIDS, LDL-C, triglycerides, IL-6, and hsCRP. Values of lipid measures, lipoprotein particle concentrations, and inflammatory biomarkers were log e -transformed prior to analysis. Estimates of the percentage difference between treatment groups in lipid biomarkers at the 2 and 6 month visits were estimated by exponentiating the log e -transformed treatment differences. Analyses were performed using SAS (version 9.1). All reported P values are two-sided.
Results

Study sample characteristics
Baseline characteristics of the drug conservation and viral suppression groups were similar and are given in Table 1 . Median level of TC was 161 mg/dL; 84% had a TC less than 200 mg/dl. Approximately 7% of participants were taking lipid-lowering medication.
Correlations among baseline lipid and lipoprotein measures, inflammatory markers, CD4 þ cell count, and HIV RNA level are given in Table 2 . LDL-C, LDL-P, and ApoB were positively correlated (range of correlations 0.74-0.75); HDL-C, total HDL-P, and ApoA1 were also positively correlated (range: 0.56-0.61). HIV RNA levels were negatively correlated with HDL measures (range: À0.15 to À0.07); correlations of HIV RNA levels with LDL measures were smaller and not significantly differ from zero (range: À0.09 to 0.01). CD4 þ cell count was not significantly associated with any of the lipid and lipoprotein measures. hsCRP and IL-6 were significantly negatively correlated with the HDL measures. The correlations of hsCRP and IL-6 with LDL measures tended to be smaller and correlations were not consistent for the two inflammatory markers.
Changes in lipids and lipoproteins after 2 and 6 months: immediate (viral suppression) versus deferred (drug conservation) antiretroviral therapy One hundred twenty-seven of 128 participants in the viral suppression group initiated ART following randomization, and remained on ART at 6 months 118 (92%). The most frequent nucleoside reverse transcriptase inhibitor combination used was zidovudine and lamivudine (n ¼ 40, 31%), and 68 participants (53%) started a nonnucleoside reverse transcriptase inhibitor (NNRTI) based regimen. At 6 months, 78 participants (62%) had a suppressed HIV RNA level. The most common reason for viral suppression participants stopping ART was toxicity (33%).
For the viral suppression group, HIV RNA levels were 2.07 log 10 copies/ml lower at 2 months (P < 0.001) and 2.13 log 10 copies/ml lower at 6 months (P < 0.001), compared with drug conservation group. CD4 þ cell count declines in the drug conservation group and increases in the viral suppression group resulted in a difference between groups of 117 cells/ml at 2 months and 191 cells/ml at 6 months (P < 0.001).
Changes in HDL-related measures (HDL-P concentrations and ApoA1 levels) over follow-up by treatment group are presented in Fig. 1 and Table 3 . When compared with the drug conservation group, those in the viral suppression group had 11.8% higher total HDL-P concentration and 8.0% higher ApoA1 levels at month 2, which persisted at month 6. At month 6, the median change in total HDL-P was 0.4 nmol/l for the drug conservation group and 2.2 nmol/l for the viral suppression group [a 12.9% difference; 95% confidence interval (CI) 7.1-19.1]; the median change in ApoA1 was 0.05 g/l for the drug conservation group and 0.12 g/l for the viral suppression group (8.8% difference; 95% CI 3.7-14.1).
After adjusting for traditional CVD risk factors (see Methods section) and baseline hsCRP and IL-6 levels, differences in total HDL-P and ApoA1 levels remained significant at 6 months (data not shown).
At months 2 and 6, there were no significant differences between viral suppression and drug conservation groups in total LDL-P or VLDL-P concentrations (at month 6, 95% CI for percentage difference between groups wereÀ6.1 to 5.0 for LDL-P and À6.3 to 16.4 for VLDL-P). ApoB levels were 5.8% higher for the viral suppression compared with drug conservation group (P ¼ 0.03) at month 2 but did not differ at month 6 (95% CI for percentage difference was À3.6 to 6.5). As a consequence of the increase in ApoA1 levels, the ratio of ApoB to ApoA1 was 7.0% lower for the viral suppression compared with the drug conservation group at month 6 (P ¼ 0.008; Fig. 1 ).
When viral suppression participants who did not initiate ART (n ¼ 1) and drug conservation participants who initiated ART before 6 months (n ¼ 14) are excluded, the corresponding differences at month 6 were 12.0% for total HDL-P concentrations (P < 0.001), 8.1% for ApoA1 (P ¼ 0.002), À0.4% for total LDL-P (P ¼ 0.90), and 2.1% for ApoB (P ¼ 0.42). When comparisons were restricted to participants with no prior ART exposure, differences at month 6 were smaller for total HDL-P concentrations (4.7%; P ¼ 0.17) and but similar for ApoA1 (7.9%; P ¼ 0.03). The median change [interquartile range (IQR)] and percentage differences (viral suppression compared with drug conservation group) for large, medium, and small HDL-P subclasses over follow-up are presented in Table 3 . The increase in total HDL-P among viral suppression participants at month 6 is accounted for primarily by increases in large and medium HDL-P concentrations. There was no treatment effect at 6 months for small LDL-P (95% CI for viral suppression-drug conservation difference was À23.0 to 13.4), but an increase in large LDL-P was seen (20.6%; 95% CI 0.5-44.8; P ¼ 0.04).
Predictors of high-density lipoprotein particle and apolipoprotein A1 changes after 6 months in the viral suppression group Among viral suppression participants, increases in total HDL-P concentration and ApoA1 levels at 6 months were inversely correlated with the decline in the levels of HIV RNA (r ¼ À0.28, P ¼ 0.002 and r ¼ À0.20, P ¼ 0.04, respectively), hsCRP (r ¼ À0.41, P < 0.001 and r ¼ À0.34, P < 0.001, respectively), and IL-6 (r ¼ À0.28, P ¼ 0.003 and r ¼ À0. 19 , P ¼ 0.05, respectively). Consistent with this, viral suppression participants with an HIV RNA level less than 400 copies/ml at 6 months demonstrated larger improvements in total HDL-P (16.1%; P < 0.001) and ApoA1 (19.1%; P < 0.001) than those with HIV RNA levels that were persistently detectable at month 6 (4.8% for HDL-P, P ¼ 0.15; 9.1% for ApoA1, P ¼ 0.01). Descriptions of changes in hsCRP and IL-6 levels among this sample have been previously published [16] .
Baseline predictors of change in total HDL-P and ApoA1 at 6 months for viral suppression participants are summarized in Web Appendix Tables A1 and A2 (http:// links.lww.com/QAD/A178). In univariate models, higher levels of hsCRP and IL-6, but not CD4 þ cell count or HIV RNA level or any other baseline covariate considered (with the exception of baseline level of LDL-C and HDL-P), were associated with greater increases in total HDL-P (P < 0.001 and P ¼ 0.008, respectively). Findings were similar for baseline hsCRP levels predicting increases in ApoA1 levels, although baseline IL-6 did not reach significance (P ¼ 0.002 and P ¼ 0.15, respectively). In multiple regression models, baseline hsCRP and IL-6 were independently associated with subsequent changes in total HDL-P (P ¼ 0.004 and 0.05, respectively) and ApoA1 (P ¼ 0.002 and 0.05, respectively).
Subgroup comparisons: differences in high-density lipoprotein changes between treatment groups according to level of HIV RNA, high-sensitivity C-reactive protein and interleukin 6 at baseline The findings indicating that hsCRP and IL-6 predicted changes in HDL-P and ApoA1 at 6 months for viral Inflammation, HDL and initiation of antiretroviral therapy Baker et al. 2137 Table 2 . Correlation between log-transformed lipid and lipoprotein measures with CD4 cell count, HIV RNA level and biomarkers at baseline: Strategies for Management of Antiretroviral Therapy participants not taking antiretroviral therapy at study entry. (0.075)
Lipoprotein particle concentrations, lipid levels and biomarkers were log e , and HIV RNA log 10 , transformed prior to comparisons. ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; HDL-C, highdensity lipoprotein cholesterol; HDL-P, high-density lipoprotein particle; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; LDL-C, low-density lipoprotein cholesterol; LDL-P, low-density lipoprotein particle; VLDL-P, very low density lipoprotein particle.
suppression participants motivated subgroup analyses that are depicted in Fig. 2 . When subgroups defined by tertile of baseline levels of hsCRP and IL-6 are examined, an interaction is present -that is, among those with higher levels of inflammation at entry, the effect of treatment (viral suppression-drug conservation differences) on HDL measures at 6 months is greater than for those with lower levels of these inflammatory markers at entry (Fig. 2) . The interaction between treatment group and HIV RNA level at baseline was not significant. When HDL subclasses were examined separately, participants with higher baseline IL-6 levels demonstrated greater improvements in large HDL-P (P ¼ 0.05 for interaction) and small HDL-P (P ¼ 0.05 for interaction), but not for medium HDL-P.
Discussion
We describe longitudinal changes in lipoprotein particle concentrations and levels of ApoB and ApoA1, which may more accurately reflect pro-atherogenic and antiatherogenic potential than traditional cholesterol indices, among participants with untreated HIV infection randomized to immediate verses deferred ART initiation. We found that starting ART led to increases in the number of HDL-P and levels of the HDL-associated protein ApoA1 and an improvement in the ApoB/A1 ratio. The effect of immediate versus deferred ART on HDL-P and ApoA1 varied according to the degree of inflammation (reflected in IL-6 and hsCRP levels) at baseline and increases in HDL measures were inversely and P values are included for the relative differences for VS compared with DC participants at month 2 (11.8% for HDL-P, 8.0% for ApoA1, and 5.8% for ApoB) and month 6 (12.9% for HDL-P, 8.8% for ApoA1, and À7.0% for ApoB/ApoA1). ART, antiretroviral therapy; DC, drug conservation; VS, viral suppression. correlated with changes in hsCRP and IL-6 for those initiating ART. Taken together with other reports, these data suggest that HIV-associated dyslipdiemia is, in part, related to chronic inflammation, and that the effect of ART on HDL changes could be mediated by suppressing inflammation.
The association between HIV infection, or HIV replication, and low HDL is well established [2, 3, 18] . On a molecular level, the HIV-nef protein blocks ATPbinding cassette transporter A1 (ABCA1)-dependent cholesterol efflux from monocyte or macrophages to HDL-P, resulting in intracellular accumulation of lipids (e.g., foam cells) [5, 6] . The ability of HDL to promote cholesterol efflux from lipid-laden macrophages (so called 'cholesterol efflux capacity') is an independent predictor of carotid intima-media thickness and obstructive coronary lesions by angiography, even independent of the plasma HDL-C level itself [19] . In the later stages of reverse cholesterol transport, HIV infection upregulates cholesteryl ester transfer protein activity, which facilitates the transfer of cholesterol to apoB-containing lipoproteins (e.g., VLDL and LDL) in exchange for triglycerides [20] . Coupled with HIV-related increases in triglycerides [21] , the net effect is a preferential delivery of cholesterol to extra-hepatic cells including the vessel wall in the context of HIV infection.
Recent findings by Feeney et al. [22] have further demonstrated that intracellular cholesterol accumulation in monocytes from HIV-infected participants is inversely correlated with traditional HDL-C levels (but not with LDL-C), whereas cholesterol accumulation in HIVnegative controls is correlated with LDL-C levels (but not with HDL-C). This difference highlights the unique features of HIV-associated dyslipidemia, and this effect on reverse cholesterol transport appears to have clinical implications. In the SMART trial, HDL-C and HDL-P were stronger predictors of CVD risk than the corresponding LDL measures [23] . Our findings build on these data and show that improvements in HDL-P after starting ART primarily reflect increases in large HDL-P, which would be consistent with improved cholesterol efflux from monocytes and macrophages into nascent smaller HDL particles.
An acute-phase inflammatory response, independent of HIV infection, also results in lower levels of HDL-C and 2 . Effect of antiretroviral therapy treatment on total high-density lipoprotein particles and ApoA1 levels when stratified by baseline level of inflammatory biomarkers or HIV RNA. The percentage difference (VS-DC groups) at 6 months in total highdensity lipoprotein particle (HDL-P) and ApoA1 is presented separately for subgroups defined by baseline levels (in tertiles) of highsensitivity C-reactive protein (hsCRP), IL-6, and HIV RNA. The percentage difference is adjusted for baseline level of HDL-P and ApoA1, respectively, and thus represents the change in these lipoprotein measures 6 months after starting ART. P values represent the interaction term of baseline biomarker level and treatment effect at 6 months. The degree of improvement in total HDL-P and ApoA1 was dependent on the degree of inflammation (reflected in hsCRP and IL-6 levels), but not the HIV RNA level, at baseline. ART, antiretroviral therapy; DC, drug conservation; VS, viral suppression.
ApoA1 and impaired cholesterol efflux from macrophages [4, 24] . For example, low HDL-C levels have been described in patients with acute infections and rheumatologic diseases, and cholesterol efflux to HDL-P is impaired in animal models of sepsis [25] [26] [27] . As with HIV infection, HDL changes in the context of other infections are, to some extent, a nonspecific consequence of inflammation [28] . Consistent with this, we describe increases in HDL measures that were greatest for those with the most inflammation at baseline (reflected in hsCRP and IL-6 levels). Among these same participants, hsCRP and IL-6 levels did not significantly improve after starting ART [16] . The differential effect of ART on HDL measures based on the degree of inflammation we describe was present even after controlling for the contribution of HIV RNA levels.
Elevations in traditional measures of TC, LDL-C, and triglycerides with ARTexposure are well characterized in the literature, and tend to be more pronounced after starting protease inhibitor-based regimens [29, 30] . The lack of significant increases in LDL-P and VLDL-P concentrations in this study may be due to the high proportion of participants in the SMART trial who used an NNRTI-based regimen (where LDL changes are less drastic). Several trials have reported increases in HDL-C that are greater with NNRTI-based versus protease inhibitor-based ART [31, 32] . In the SMART trial, any approved ART regimen could be used and therefore comparisons between specific regimens were not randomized.
Taken cumulatively, the consequences of HIV infection and exposure to ART contribute to a clinical phenotype that resembles the metabolic syndrome (i.e., low HDL, high triglycerides, increased waist circumference, insulin resistance, elevated blood pressure) [33] [34] [35] [36] . Inflammation is also a key component of the metabolic syndrome that may both contribute to, and be a consequence of, lipoprotein changes, insulin resistance, and visceral obesity both in HIV-infected and uninfected populations [37] [38] [39] [40] . Although effective treatments exist for elevated cholesterol levels (e.g., LDL and triglycerides), strategies to raise HDL are fewer and pharmacology-associated changes in HDL have failed to demonstrate a clear clinical benefit [41, 42] . Thus, anti-inflammatory therapies as a CVD prevention strategy, particularly in the context of HIV infection, warrant further study.
We focused these analyses on changes in novel measures of lipoprotein particle concentrations and Apo, which may be more informative for CVD risk than traditional measures of cholesterol content (e.g., HDL-C) [8] [9] [10] [11] [12] [13] . Lower HDL-P concentration and size has been independently associated with higher coronary heart disease risk in the general population [43] , and in the Cardiovascular Health Study, the large HDL-P subclass was inversely related to incident coronary heart disease [9] . In the SMART trial, large HDL-P was the only HDL subclass significantly associated with CVD risk and the ApoB/ApoA1 ratio was a stronger predictor of CVD risk than any of the individual cholesterol indices measured [23, 44] . Our findings specifically describe ART-related improvements in large HDL-P concentration and ApoB/ ApoA1 ratio. Longer-term clinical data are needed to determine the most useful lipoprotein measure for assessing and modifying clinical CVD risk among individuals with HIV infection.
Strengths of this study include use of a randomized control group of participants deferring ART when characterizing ART-related changes in lipoprotein measures. A limitation is the lack of traditional lipid measures (TC, LDL-C, HDL-C, and triglycerides) at 2 and 6 months of follow-up, although changes in these parameters after starting ART have been extensively reported [2, 45] . Finally, unlike VLDL-P, measures of LDL-P or HDL-P subclasses and levels of ApoB and ApoA1 are more reliable with nonfasting specimens [7] .
In summary, ART initiation improves HDL-P number and ApoA1 levels probably as a result of reduced inflammation. It remains unclear whether the increases in HDL-P and ApoA1 following ART initiation reduce clinical CVD risk. 
